Last $51.15 USD
Change Today +0.58 / 1.15%
Volume 225.0K
RDY On Other Exchanges
New York
Natl India
As of 4:15 PM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

doctor reddy's lab-adr (RDY) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/25/14 - $53.67
52 Week Low
11/8/13 - $38.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DOCTOR REDDY'S LAB-ADR (RDY)

Related News

No related news articles were found.

doctor reddy's lab-adr (RDY) Related Businessweek News

No Related Businessweek News Found

doctor reddy's lab-adr (RDY) Details

Dr. Reddy’s Laboratories Limited operates as an integrated pharmaceutical company in India. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment produces and markets finished pharmaceutical products as branded formulations or generic finished dosages. This segment is also engaged in the operation of biologics business. The PSAI segment develops active pharmaceutical ingredients (APIs) and intermediaries, which are used as principal ingredients for finished pharmaceutical products. This segment also offers contract research services to biotech and pharmaceutical companies; and manufactures and sells APIs and steroids in accordance with the specific customer requirements. The Proprietary Products segment is involved in the discovery and development of new chemical entities and differentiated formulations for subsequent commercialization. Its differentiated formulations portfolio consists of new, synergistic combinations, and technologies that enhance safety and/or efficacy by modifying pharmacokinetics of existing medicines. This segment is also involved in the Company’s specialty pharmaceuticals business, which conducts sales and marketing operations for in-licensed and co-developed dermatology products. The company’s therapeutic categories include gastro-intestinal, cardiovascular, pain management, and oncology. It also operates in North America, Europe, Russia, other countries of the former Soviet Union, and internationally. Dr. Reddy’s Laboratories Limited has strategic partnership with GlaxoSmithKline plc to develop and market products outside India; and collaboration agreement with Merck Serono to develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies. The company was founded in 1984 and is headquartered in Hyderabad, India.

18,421 Employees
Last Reported Date: 06/26/14
Founded in 1984

doctor reddy's lab-adr (RDY) Top Compensated Officers

Co-Chairman, Managing Director, Chief Executi...
Total Annual Compensation: 6.3M
Chairman of The Board, Member of The Manageme...
Total Annual Compensation: 7.7M
Compensation as of Fiscal Year 2014.

doctor reddy's lab-adr (RDY) Key Developments

Dr. Reddy's Laboratories Ltd. Announces the Launch of Levalbuterol Inhalation Solution, USP

Dr. Reddy's Laboratories Ltd. announced that it has launched Levalbuterol Inhalation Solution, USP 0.31 mg /3 mL, 0.63 mg /3 mL, 1.25 mg /3 mL Unit-Dose Vials, a therapeutic equivalent generic version of XOPENEX(R) (levalbuterol hydrochloride) inhalation solution in the U.S. market on September 23, 2014, approved by the United States Food & Drug Administration (USFDA). Dr. Reddy's Levalbuterol Inhalation Solution, USP 0.31 mg /3 mL, 0.63 mg /3 mL, 1.25 mg /3 mL are available in Unit-Dose Vials of (5 x 3 mL) carton of 25. Levalbuterol Inhalation Solution, USP is only for use with a nebulizer.

Dr. Reddy's Laboratories Ltd. Presents at 10th Annual India Investment Forum, Sep-25-2014 08:30 AM

Dr. Reddy's Laboratories Ltd. Presents at 10th Annual India Investment Forum, Sep-25-2014 08:30 AM. Venue: The Pierre, 2 East 61 st Street at Fifth Avenue, New York, NY 10065, United States. Speakers: Umang Vohra, Head of North America Generics Business, Executive Vice President and Member of Management Council.

Dr. Reddy's Mulls Acquisitions

Dr. Reddy's Laboratories Ltd. (BSE:500124) is seeking acquisitions. "We still continue to be interested in Japan. We are exploring all options. The priority is to get into the right plan to enter into the Japanese market. So the options for us are to seek a partner, acquire a company or do it organically," Dr Reddy's said.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RDY:US $51.15 USD +0.58

RDY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cipla Ltd/India 628.45 INR 0.00
Croda International PLC 2,191 GBp -38.00
Endo International PLC $65.04 USD +0.38
Lupin Ltd 1,391 INR 0.00
Symrise AG €43.49 EUR +0.175
View Industry Companies

Industry Analysis


Industry Average

Valuation RDY Industry Range
Price/Earnings 21.9x
Price/Sales 3.7x
Price/Book 5.3x
Price/Cash Flow 21.9x
TEV/Sales 3.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DOCTOR REDDY'S LAB-ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at